ARTICLE | Clinical News
Pixuvri pixantrone: SPA submitted
August 9, 2010 7:00 AM UTC
Cell Therapeutics submitted an SPA to FDA for a proposed Phase III trial designed to compare pixantrone plus Rituxan rituximab against current standard regimens. The company hopes to start the trial ...